key: cord-0736864-t6kg03h6
authors: Loo, Lay Khoon; Salim, Omar; Liang, Di; Goel, Aimee; Sumangala, Salini; Gowda, Ashwin S.; Davies, Brendan; Rajabally, Yusuf A.
title: Acute‐onset polyradiculoneuropathy after SARS‐CoV2 vaccine in the West and North Midlands, United Kingdom
date: 2021-11-26
journal: Muscle Nerve
DOI: 10.1002/mus.27461
sha: c5531b4eef8278817476102435b89b98c5578779
doc_id: 736864
cord_uid: t6kg03h6

INTRODUCTION/AIMS: We aimed to determine whether specific severe acute respiratory syndrome coronavirus 2 (SARS‐CoV2) vaccines may be associated with acute‐onset polyradiculoneuropathy and if they may result in particular clinical presentations. METHODS: We retrospectively reviewed records of all persons presenting with acute‐onset polyradiculoneuropathy from January 1, 2021, to June 30, 2021, admitted to two Neuroscience centers, of the West and North Midlands, United Kingdom. We compared subjects with previous SARS‐CoV2 vaccine exposure with a local cohort of persons with acute‐onset polyradiculoneuropathy admitted between 2005 and 2019 and compared admission numbers for the studied time frame with that of the previous 3 years. RESULTS: Of 24 persons with acute‐onset polyradiculoneuropathy, 16 (66.7%) presented within 4 weeks after first SARS‐CoV2 vaccine. Fourteen had received the AstraZeneca vaccine and one each, the Pfizer and Moderna vaccines. The final diagnosis was Guillain‐Barré syndrome (GBS) in 12 and acute‐onset chronic inflammatory demyelinating polyneuropathy in 4. Among AstraZeneca vaccine recipients, facial weakness in nine persons (64.3%), bulbar weakness in seven (50%), and the bifacial weakness and distal paresthesias GBS variant in three (21.4%), were more common than in historical controls (P = .01; P = .004, and P = .002, respectively). A 2.6‐fold (95% confidence interval: 1.98–3.51) increase in admissions for acute‐onset polyradiculoneuropathy was noted during the studied time frame, compared to the same period in the previous 3 years. DISCUSSION: Despite a low risk, smaller than that of SARS‐CoV2 infection and its complications, exposure to the first dose of AstraZeneca SARS‐CoV2 vaccine may be a risk factor for acute‐onset polyradiculoneuropathy, characterized by more common cranial nerve involvement.

All patients with a new diagnosis of GBS or acute-onset CIDP who had received a first dose of any SARS-CoV2 vaccine in the preceding 4 weeks before onset of neurological symptoms were identified. Vaccine type and delay to onset from vaccine administration was documented. Electrophysiological subtype was determined at initial presentation for GBS, as per recent criteria, 9 as was fulfillment of criteria for CIDP in patients with a subsequent chronic disease course. 8 We Table 1 . Mean time of onset after vaccination was 14.4 days (SD: 6.8). All but two had received the AstraZeneca vaccine. None reported antecedent infections or vaccinations. Electrophysiological results are detailed in Table 1 . The subject with equivocal electrophysiology was diagnosed with classic GBS with quadriparesis, areflexia, and bifacial weakness. CSF protein was 210 mg/dL. The subject with normal electrophysiology was diagnosed clinically with the bifacial weakness and distal paresthesias GBS variant and had a CSF protein of 89 mg/dL. All 16 persons were treated with intravenous immunoglobulin at initial presentation. Four persons (25%) had a subsequent clinical course and electrophysiology meeting criteria for acute-onset CIDP. 8 These subjects were subsequently successfully re-treated with intravenous immunoglobulin in two, corticosteroids in one, and plasma exchanges in two. Outcomes are detailed in Table 1 . 

We found that our centers experienced a 2.6-fold increase in number of admissions for GBS during the study period, compared to the same period in the previous 3 years. We believe it is possible that this may be due to the cases of polyradiculoneuropathy post-SARS-CoV2 vaccination. Reduced exposure to other pathogens through distancing measures and hand hygiene was postulated as cause for reduced GBS incidence in the first months of the pandemic in 2020, 10 13 Whereas no specific measures for younger persons were initially taken, 14 risk stratification by age was subsequently implemented in the United Kingdom. 15 The mechanisms involved in post-vaccination inflammatory neuropathy may relate to antibody production cross-reacting with neural components. This may involve the SARS-CoV2 spike protein. Of note, in addition to the AstraZeneca vaccine, the Johnson&Johnson/ Janssen vaccine, has also recently been reported to precede GBS in 100 patients. 16 This has not been the case in similar proportions with mRNA vaccines. It is also possible that the immune target in the cases following AstraZeneca vaccination may be related to the adenovirus vector, which may explain the rarity of cases after mRNA vaccines. 17 In the absence of further data, the possibility of specific immune mechanisms in polyradiculoneuropathy, as postulated for VITT in relation to adenovirus-DNA vaccines cannot, therefore, be excluded.

Our study is limited by its retrospective design and the small region covered by our institutions. Random clustering may be argued as a potential explanation. However, occurrence predominantly after the first dose of the AstraZeneca vaccine, clinical differences including more common cranial involvement, and increased admission rates for acute-onset polyradiculoneuropathy at our institutions from the onset of the vaccination campaign, raise the need for further studies.

Temporal association does not imply causality. 18 The overwhelmingly beneficial effect of vaccines on the current SARS-CoV2 pandemic clearly and repeatedly needs emphasizing, 19 in comparison to the low risk of adverse events, including GBS or acute-onset CIDP. However, at T A B L E 1 Characteristics of 16 persons with acute-onset polyradiculoneuropathy within 4 wk of any first dose of SARS-CoV2 vaccination 

We confirm that we have read the Journal's position on issues involved in ethical publication and affirm that this report is consistent with those guidelines.

Anonymised data available at reasonable request. In-hospital mortality 1 (7.1%) 7 (6.1%) 1.0

Bold values are statistically significant results of the study.

Coronavirus vaccineweekly summary of Yellow Card reporting

Guillain-Barre syndrome following ChadOx1-S/NVCoV19 vaccine

Guillain-Barre syndrome variant occurring after SARS-CoV2 vaccination

Guillain-Barre syndrome following the first dose of chimpazee adeno-virus vectored COVID-19 vaccine, ChAdOx1

Exacerbating Guillain-Barre syndrome eight days after vectorbased COVID19 vaccination. Case Rep Infect Dis

Neurological complications of COVID19: Guillain-Barre syndrome following Pfizer COVID-19 vaccine

for the GBS Classification Group. Guillain-Barré and Miller Fisher syndromes: new diagnostic classification

European Academy of Neurology/Peripheral Nerve Society Guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint Task Force -Second Revision

Electrophysiological diagnosis of Guillain-Barré syndrome subtype: could a single study suffice?

Epidemiological and cohort study finds no association between COVID-19 and Guillain-Barre syndrome

Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 5-8

Blood clots and bleeding events following BNT162b2 and ChAdOx1 nCoV-19 vaccine: an analysis of European data

Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination

Covid-19: AstraZeneca vaccine is approved in EU with no upper age limit

COVID-19 vaccination and blood clotting

Food & Drug Administration. Coronavirus (COVID19)

Mechanisms of immunothrombosis in vaccine-induced thrombotic thrombocytopenia (VITT) compared to natural SARS-CoV-2 infection

Guillain-Barre syndrome in the placebo and active arms of a COVID-19

Quelling public fears about Guillain-Barre syndrome and COVID-19 vaccination

Neurological complications after first dose of COVID-19 vaccines and SARS-CoV-2 infection